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Introduction
Initial studies on vaccination against Haemonchus contortus
in 1997 have shown that total worm protein extracts were
able to elicit a partially protective immune response, how-
ever attempts to enhance this response with a powerful mu-
cosal adjuvant namely E. coli heat-labile enterotoxin (HLT)
failed. Based on our findings and current literature it was
suggested that development of anti-parasite vaccines should
emphasise studies on immunostimulants that can enhance the
response in the gut rather than selecting protein antigens
from gel bands that were not likely to elicit protective immu-
nity. Using rapid celJ assay screening methods we have dis-
covered an aqueous extract from Solanum torvum that is
strongly mitogenic for splenic lymphocytes (Israf et al. un-
published data). We have tested this extract several times in a
rodent-non-replicating antigen model and have shown that it
is as effective as cholera toxin in enhancing mucosal immune
responses. The results of these trials are presented.
Materials and Methods
Three trials were conducted with outbred female ICR mice.
In trial 1, 10 groups of mice were given various doses of So-
lanum extract as an adjuvant to bovine serum albumin via the
intraperitoneal route. Boosters were given and the immune
response throughout a 4-month period was analysed. In trial
2 and 3, mice received similar doses as in trial 1 however the
route of inoculation was via oral lavage. The main emphasis
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of these trials was to examine the ability of Solanum extracts
to stimulate mucosal immune effector mechanisms towards
ovalbumin. Assays used included enzyme immunoassay for
detection of antibody isotypes in various tissues and serum.
Enzyme immunospot was used to study cytokine responses
of lymphoid tissue using monoclonal antibodies towards
IFM-y, IL-2, IL-4 and IL-S.
Results and Discussion
In trial 1: We demonstrated a significant enhancement in
anti-BSA IgG titers when the 10Vj.estdose of Solanum was
used (2 ug). We also demonstrated that following a final
booster, the intestinal levels of both anti-BSA IgA and IgG'
were significantly elevated. Trial 2 demonstrated that an oral
booster with ovalbumin/O.Smg Solanum was able to signifi-
cantly elevate intestinal and faecal IgA concentration and
stimulate both Thl and Th2 cells as determined by analysis
of cytokine production. Trial 3 extended the findings of trial
2 in that it was shown that a very low dose of Solanum (2 ug)
administered orally with ovalbumin was far more superior in
generating both local and peripheral antibody and cytokine
responses. This trial also demonstrated that 2ug of Solanum
can enhance immune effector mechanisms in the lung, an ex-
ample of enhanced mucosal homing. There is no doubt that
this extract is truly stimulatory for lymphocytes and has great
potential to replace the current mucosal adjuvants that are
more toxic in nature. We plan to acquire further data on the
mechanism of action and study the enhancing effects in a
prototype Haemonchus vaccine.
Conclusions
Solanum extracts are very effective in enhancing local and
peripheral effector mechanisms towards model protein anti-
gens. They target lymphocytes by enhancing synthesis and
secretion of antibodies and cytokines. However our data sug-
gest that the crude extract contains both immunostimulatory
and immunosuppressive factors. This theory is based on the
fact that a reduction of the dose to as little as 2 ug leads to
enhanced responses. It is therefore necessary to fractionate
the components for future studies.
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